United States Federal Circuit
Novo Nordisk Pharm. v. Bio-Tech. Gen. Corp., 04-1581
In a patent dispute concerning human growth hormones, the district court improperly ruled that plaintiff's patent was invalid based on anticipation under 35 U.S.C. section 102(a).
Appellate Information
- Decided 10/05/2005
- Published 10/05/2005
Judges
- SCHALL, Circuit Judge., Before SCHALL, Circuit Judge, ARCHER, Senior Circuit Judge, and BRYSON, Circuit Judge.
Court
- United States Federal Circuit
Counsel
- For Appellant:
- Steven E. Lipman, Darby & Darby, P.C., of New York, New York, argued for plaintiffs-appellants. Of counsel were James Edward Hanft, Paul M. Zagar, Jay P. Lessler, Kevin L. Reiner, Robert Schaffer and Joseph R. Robinson.
- For Appellees:
- John W. Bateman, Kenyon & Kenyon, of Washington, DC, argued for defendants-appellees. On the brief was Richard L. DeLucia, of New York, New York. Of counsel were Steven J. Lee, and Thomas J. Meloro, of New York, New York, and Kenneth R. Corsello, of Washington, DC.